Overview: Treponema Pallidum Hemagglutination TestIntroduction: The Treponema Pallidum Hemagglutination Test detects treponema antibodies to diagnose syphilis, causing sores or rash. Following 2023 CDC guidelines, it uses immunoassays for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in serology for patients with suspected syphilis.
Other Names: TPHA Assay, Syphilis Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: TPHA testing began in the 1960s with syphilis research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects treponema antibodies to diagnose syphilis, guides treatment, and evaluates patients with sores or rash.
Test Parameters: 1. Treponema Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of sores, rash, or syphilis exposure.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document sores, rash, or history of syphilis exposure. Include current medications, especially antibiotics.
Consent: Written consent required, detailing the tests purpose, syphilis implications, and risks of sample collection.
Procedural Considerations: Uses hemagglutination assay to detect treponema antibodies. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for syphilis diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other infections may reduce specificity.
Clinical Significance: Positive antibodies confirm syphilis, guiding antibiotic therapy. Negative results may require RPR or VDRL testing.
Specialist Consultation: Consult an infectious disease specialist for result interpretation and treatment planning.
Additional Supporting Tests: RPR, VDRL, or FTA-ABS to confirm syphilis diagnosis.
Test Limitations: Non-specific for syphilis stage; clinical correlation is needed. Sample quality affects sensitivity.
References: CDC Syphilis Guidelines, 2023; Clinical Infectious Diseases, Peeling RW, 2022.
